Release Date: 10/12/14 08:38 Summary: Senex to retain strong net cash position at end FY15 Price Sensitive: Yes Download Document 181.37KB Download
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%